Condition
Recurrent Liposarcoma
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (2)
Trial Status
Completed2
Terminated1
Active Not Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06414434Phase 1Active Not Recruiting
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
NCT04213794Early Phase 1Terminated
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
NCT02357810Phase 2Completed
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
NCT01653028Phase 2Completed
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Showing all 4 trials